19.96
Amphastar Pharmaceuticals Inc stock is traded at $19.96, with a volume of 592.45K.
It is up +0.66% in the last 24 hours and down -30.23% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$19.83
Open:
$19.97
24h Volume:
592.45K
Relative Volume:
1.48
Market Cap:
$917.21M
Revenue:
$723.31M
Net Income/Loss:
$111.63M
P/E Ratio:
8.8503
EPS:
2.2553
Net Cash Flow:
$111.01M
1W Performance:
-28.64%
1M Performance:
-30.23%
6M Performance:
-31.62%
1Y Performance:
-27.73%
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals Inc
|
19.96 | 911.23M | 723.31M | 111.63M | 111.01M | 2.2553 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
AMPH SEC FilingsAmphastar Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Amphastar Pharmaceuticals Hits Day Low of $19.83 Amid Price Pressure - Markets Mojo
Amphastar Pharmaceuticals Stock Plummets to New 52-Week Low of $19.83 - Markets Mojo
Royce & Associates LP Raises Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Potential Upside of 38% Attracts Investor Attention - DirectorsTalk Interviews
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth - Finviz
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.’s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth - Yahoo Finance
Cash per share of Amphastar Pharmaceuticals, Inc. – DUS:29A - TradingView
Amphastar FDA Wins And Pipeline Expansion Contrast With Weak Earnings And Valuation - Yahoo Finance
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript - Insider Monkey
Amphastar Pharmaceuticals Stock Hits New 12-Month Low After Analyst Downgrade - National Today
AMPH Stock (-24%): Q4 Earnings Miss Sparks Aggressive Liquidation - Trefis
Amphastar Pharmaceuticals Q4 2025 Report: Revenue Miss, Stock DeclineNews and Statistics - IndexBox
Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 12-Month Low After Analyst Downgrade - MarketBeat
Amphastar stock hits 52-week low at $20.38 By Investing.com - Investing.com Australia
Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results - MarketBeat
Amphastar Pharmaceuticals Inc (29A.BE) Stock Price, News, Quote & History - Yahoo Finance
Amphastar stock hits 52-week low at $20.38 - Investing.com
Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today - Finviz
Wells Fargo & Company Has Lowered Expectations for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $30.00 at Needham & Company LLC - MarketBeat
Amphastar Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham cuts Amphastar stock price target on Q4 miss, weak sales - Investing.com
TD Asset Management Inc Sells 103,038 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Amphastar Stock Pre-Market (-15%): Q4 Earnings and Revenue Miss - Trefis
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narratives Despite Low 9.5x P/E - Sahm
Amphastar Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Amphastar’s Q4 2025 Misses Estimates, Stock Dips By Investing.com - Investing.com Canada
Amphastar (AMPH) Q4 2025 Earnings Call Transcript - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7% - Finviz
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Amphastar Pharmaceuticals Inc. (AMPH) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Amphastar Pharmaceuticals Inc. (AMPH) stock falls on Q4 2025 Earnings - Quiver Quantitative
Amphastar Pharmaceuticals Reports Financial Results for Q4 and Full Year 2025 - TradingView
Earnings Flash (AMPH) Amphastar Pharmaceuticals, Inc. Reports Q4 Revenue $183.1M, vs. FactSet Est of $190.1M - marketscreener.com
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 - ACCESS Newswire
Amphastar Pharmaceuticals Q4 2025 Earnings: Release Date & Analyst OutlookNews and Statistics - IndexBox
Amphastar earnings on deck: Can pipeline offset flat growth? By Investing.com - Investing.com UK
Amphastar: Fourth Quarter Financial Overview - Bitget
Insights Ahead: Amphastar Pharma's Quarterly Earnings - Benzinga
Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect - Yahoo Finance UK
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 14.60% Potential Upside - DirectorsTalk Interviews
Amphastar Announces FDA Approval for Ipratropium Bromide HFA - ACCESS Newswire
FDA clears Amphastar rival to Atrovent inhaler, 180-day exclusivity - Stock Titan
(AMPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):